These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22336881)

  • 21. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.
    Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN
    Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer.
    Crawford ED; Petrylak DP; Higano CS; Kibel AS; Kantoff PW; Small EJ; Shore ND; Ferrari A
    Can J Urol; 2015 Dec; 22(6):8048-55. PubMed ID: 26688132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood cells and their use in active immunotherapy of prostate cancer.
    Zhang SY; Thara E; Quinn DI; Dorff TB
    Hum Vaccin Immunother; 2012 Apr; 8(4):528-33. PubMed ID: 22370509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention.
    Jarosławski S; Toumi M
    BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapeutics for the treatment of prostate cancer: a patent landscape based on key therapeutic mechanisms of actions.
    Harris E
    Pharm Pat Anal; 2018 Jan; 7(1):47-57. PubMed ID: 29227196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.
    Holl EK; McNamara MA; Healy P; Anand M; Concepcion RS; Breland CD; Dumbudze I; Tutrone R; Shore N; Armstrong AJ; Harrison M; Wallace JA; Wu Y; George DJ
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):588-592. PubMed ID: 30980027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sipuleucel-T: a therapeutic cancer vaccine for the treatment of castration- or hormone-refractory prostate cancer.
    Bulloch MN; Elayan MM; Renfroe HR
    Expert Rev Clin Pharmacol; 2011 Nov; 4(6):685-92. PubMed ID: 22111853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New treatments for metastic prostate cancer.
    Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
    Garcia JA; Dreicer R
    Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer vaccines.
    Michael A; Relph K; Annels N; Pandha H
    Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
    Dawson NA; Roesch EE
    Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
    Thara E; Dorff TB; Pinski JK; Quinn DI
    Maturitas; 2011 Aug; 69(4):296-303. PubMed ID: 21621934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Provenge: revolutionary technology or ethical bust?
    Dickerson JB
    Hum Vaccin; 2011 Apr; 7(4):477-80. PubMed ID: 21451262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.
    Buonerba C; Ferro M; Di Lorenzo G
    Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer.
    Dreicer R
    Can J Urol; 2014 Apr; 21(2 Supp 1):93-7. PubMed ID: 24775730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.
    GuhaThakurta D; Sheikh NA; Fan LQ; Kandadi H; Meagher TC; Hall SJ; Kantoff PW; Higano CS; Small EJ; Gardner TA; Bailey K; Vu T; DeVries T; Whitmore JB; Frohlich MW; Trager JB; Drake CG
    Clin Cancer Res; 2015 Aug; 21(16):3619-30. PubMed ID: 25649018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.
    Fong L; Carroll P; Weinberg V; Chan S; Lewis J; Corman J; Amling CL; Stephenson RA; Simko J; Sheikh NA; Sims RB; Frohlich MW; Small EJ
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25255802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
    Antonarakis ES; Drake CG
    Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.